Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995 May 01;85(9):2516-20
Date
05/01/1995Pubmed ID
7537119DOI
10.1182/blood.v85.9.2516.bloodjournal8592516Scopus ID
2-s2.0-0028933071 (requires institutional sign-in at Scopus site) 54 CitationsAbstract
Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor, has multiple effects on lymphoid development. In addition, it has been previously reported that serum levels of IL-10 correlate with failure-free and overall survival in patients with non-Hodgkin's lymphoma. In this study, we used a sensitive enzyme-linked immunosorbent assay specific for human IL-10 (lower limit of sensitivity, 5 pg/mL) to measure serum levels in 52 newly diagnosed patients with diffuse large cell lymphoma and at least one adverse prognostic feature who were subsequently treated in a uniform way. Lymphoma patients had significantly higher serum levels of IL-10 (median, 7.98 pg/mL; range, < or = 5 to 27,143 pg/mL) than healthy volunteers (N = 50; median, < or = 5 pg/mL; range, < or = 5 to 19.21 pg/mL) (P = .0000012). Individuals with B symptoms had significantly higher serum levels of IL-10 than those without them (P = .03), but there was no correlation between IL-10 levels and any of the other prognostic variables analyzed, including age, lactic dehydrogenase, beta 2-microglobulin levels, performance status, bulky disease, Ann Arbor stage, or International Index score. More importantly, we found no correlation between IL-10 levels and the achievement of complete remission, nor with failure-free survival or overall survival. We conclude that in a uniform population of untreated patients with diffuse large cell lymphoma, serum levels of IL-10 do not appear to have any prognostic value.
Author List
Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Bleomycin
Cisplatin
Cyclophosphamide
Cytarabine
Doxorubicin
Enzyme-Linked Immunosorbent Assay
Etoposide
Female
Follow-Up Studies
Humans
Ifosfamide
Interleukin-10
Life Tables
Lymphoma, Large B-Cell, Diffuse
Male
Mesna
Methotrexate
Methylprednisolone Hemisuccinate
Middle Aged
Mitoxantrone
Neoplasm Proteins
Prognosis
Risk Factors
Sensitivity and Specificity
Severity of Illness Index
Survival Analysis
Treatment Outcome
Vincristine